The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics ...
13don MSN
New laser treatment could stop blindness even before it starts and restore early eye health
Scientists have developed a revolutionary laser treatment to prevent blindness. This non-invasive therapy uses ultra-short ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...
Medpage Today on MSN
Wet AMD: Tips on Navigating Anti-VEGF Drug Options
According to Liu, his preferred option is faricimab, a fairly new agent that was FDA-approved for wet AMD in 2022. The drug ...
Outlook Therapeutics (OTLK) stock rises as the company's wet AMD therapy ONS-5010 undergoes FDA review, with a decision ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...
Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on ...
We’re excited to present a review of our robust data package at OIS, highlighting our momentum toward advancing this innovation into clinical evaluation.” About VLTR-559 VLTR-559 is a long-acting anti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback